Abstracts tagged "dermatomyositis"

Abstract Number: 275 • 2016 ACR/ARHP Annual Meeting
In Vitro Activation of Type I Interferon Pathway Reproduces the Characteristics Damages Observed in Dermatomyositis Patients
Leandro Ladislau^1,2,3, Xavier Suárez-Calvet^1,4, Claudia Benjamin³, Ségolène Toquet¹, Benjamin Terrier⁵, Flore Rozenberg⁶, Vincent Mouly¹, Gillian Butler Browne⁷, Werner Stenzel⁸, Olivier Benveniste⁹ and Yves Allenbach¹⁰, ¹Sorbonne Universités, UPMC Univ Paris 06, INSERM UMRS_974, CNRS FRE 3617, Center of Research in Myology., Paris, France, ²Programa de Ciências Biomédicas, Instituto de Ciências Biomédicas, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil, ³Instituto de Biofísica Carlos Chagas Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil, ⁴Neuromuscular Diseases Unit, Neurology, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona and Institut de Recerca Sant Pau., Barcelona, Spain, ⁵Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, ⁶Departement de Virologie, Hôpital Cochin, Paris Descartes Universités, Paris, France, ⁷Sorbonne Universités UPMC Univ Paris 06, Myology research center, INSERM UMRS974, CNRS FRE3617, Pitié-Salpêtrière University Hospital, Paris, France, Paris, France, ⁸Charité-Universitätsmedizin Berlin, Berlin, Germany, ⁹Pitié-Salpêtrière University Hospital, Paris, France, ¹⁰Internal Medicine, Pitié-Salpêtrière University Hospital, Paris, France
Background/Purpose: The type I interferons (IFN-I) including IFN-a, and IFN-b are key cytokines involved in innate immune response to viral infection. Almost all cells can…
Abstract Number: 285 • 2016 ACR/ARHP Annual Meeting
Antibodies to Small Ubiquitin-like Modifier Activating Enzyme: Frequency and Characteristics of Antibody-Positive Patients in an Unselected Cohort
Anne Tebo¹, Troy Jaskowski² and Lisa Peterson¹, ¹Pathology, University of Utah School of Medicine and ARUP Laboratories, Salt Lake City, UT, ²ARUP Laboratories, Salt Lake City, UT
Background/Purpose: Antibodies to small ubiquitin-like modifier activating enzyme (SAE) are associated with diagnosis of dermatomyositis (DM). The aims of this study were to establish the…
Abstract Number: 286 • 2016 ACR/ARHP Annual Meeting
Clinical Significance and Prognostic Value of Neutrophil to Lymphocyte Ratio in Patients with Dermatomyositis
Jaehyung Hur¹, Dong Jin Go², Sang Wan Chung³, You Jung Ha³, Eun Ha Kang¹, Jin Kyun Park⁴, Eun Young Lee², Eun Bong Lee², Yeong Wook Song⁴ and Yun Jong Lee⁵, ¹Division of Rheumatology, Department of Internal Medicine, Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea, The Republic of, ²Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea, The Republic of, ³Division of Rheumatology, Department of Internal Medicine, Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea, ⁴Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea, ⁵Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea
Background/Purpose: Recent studies have suggested that neutrophil to lymphocyte ratio (NLR) could be an emerging predictive marker of disease activity or mortality in patients with…
Abstract Number: 1187 • 2016 ACR/ARHP Annual Meeting
Ultraviolet Radiation Exposures Are Associated with Dermatomyositis in a National Myositis Registry
Christine G. Parks¹, Jesse Wilkerson², Kathryn M. Rose², Abdullah Faiq³, Payam Noroozi Farhadi³, Craig S. Long⁴, Nastaran Bayat³, Hermine I. Brunner⁵, Bob Goldberg⁶, John McGrath², Frederick W. Miller³ and Lisa G. Rider³, ¹Epidemiology Branch, National Institute of Environmental Health Sciences, NIH, Durham, NC, ²Social and Scientific Systems, Inc., Durham, NC, ³Environmental Autoimmunity Group, National Institute of Environmental Health Sciences, NIH, Bethesda, MD, ⁴NOAA/National Weather Service, National Centers for Environmental Prediction Climate Prediction Center, College Park, MD, ⁵Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁶The Myositis Association, Alexandria, VA
Background/Purpose: Previous studies suggest exposure to ultraviolet (UV) radiation may be a risk factor for dermatomyositis (DM) and autoantibody phenotypes, based on differences in prevalence…
Abstract Number: 1237 • 2016 ACR/ARHP Annual Meeting
The Economic Burden of Dermatomyositis and Polymyositis in the US
J. Bradford Rice¹, Alan White¹, Philip Galebach¹, Andrea Lopez¹, Patricia Schepman², Breanna Popelar³, Michael Philbin⁴ and Elaine Boing², ¹Analysis Group, Inc., Boston, MA, ²Affiliated with Mallinckrodt Pharmaceuticals at the time this study was conducted, Hazelwood, MO, ³Xcenda, L.L.C., Palm Harbor, FL, ⁴Mallinckrodt Pharmaceuticals, Hazelwood, MO
Background/Purpose: Dermatomyositis and polymyositis (DM/PM) are inflammatory myopathies that can lead to persistent muscle weakness and disability. Although significant healthcare resource utilization (HCRU) and work…
Abstract Number: 1290 • 2016 ACR/ARHP Annual Meeting
The Usefulness of Volumetric Parameters of FDG PET/CT for Reflecting Disease Activity in Polymyositis/Dermatomyositis Patients
Atsushi Kondo¹, Hiroaki Dobashi¹, Tomohiro Kameda¹, Miharu Izumikawa¹, Shusaku Nakashima¹, Hiromi Shimada¹, Hiroki Ozaki¹, Risa Wakiya¹, Yuka Yamamoto², Yoshihiro Nishiyama³ and Norimitsu Kadowaki¹, ¹Internal Medicine Division of Hematology, Rheumatology, and Respiratory Medicine, Kagawa University, Kagawa, Japan, ²Radiology, Kagawa University, Kagawa, Japan, ³Department of Radiology, Faculty of Medicine,Kagawa University, Kagawa University, Kita-gun, Japan
Background/Purpose: Polymyositis/dermatomyositis (PM/DM) are systemic inflammatory disorders predominantly affecting skeletal muscles and skin respectively. Although muscle biopsy is the most important to the diagnosis of…
Abstract Number: 1368 • 2016 ACR/ARHP Annual Meeting
Clinical Course of Juvenile Dermatomyositis Presenting As Skin Predominant Disease
Edward J. Oberle^1,2, Dominic O. Co^3,4, Yvonne Chiu^3,4, Michelle Bayer^4,5, Adam Huber⁶, Hatice Ezgi Baris⁷ and Susan Kim⁸, ¹Pediatric Rheumatology, Nationwide Children's Hospital, Columbus, OH, ²Pediatrics, Ohio State University, Columbus, OH, ³Pediatrics, Medical College of Wisconsin, Milwaukee, WI, ⁴Children's Hospital of Wisconsin, Milwaukee, WI, ⁵Dermatology, Medical College of Wisconsin, Milwaukee, WI, ⁶Pediatric rheumatology, IWK Health Centre, Halifax, NS, Canada, ⁷Boston Children's Hospital, Boston, MA, ⁸Division of Immunology, Boston Children's Hospital, Boston, MA
Background/Purpose: Juvenile dermatomyositis (JDM) is a chronic inflammatory disorder of the skin and striated muscle. A subset of patients can present with rash only, labeled…
Abstract Number: 1376 • 2016 ACR/ARHP Annual Meeting
In Juvenile Dermatomyositis, Organ Damage Is Comparable after Median 13.5 and 21.5 Years Follow-up Time, Despite Sustained Disease Activity
Kristin Schjander Berntsen¹, Berit Flatø^1,2, Ivar Sjaastad^2,3 and Helga Sanner^1,4, ¹Department of Rheumatology, Oslo University Hospital, Rikshospitalet, Oslo, Norway, Oslo, Norway, ²Institute for Clinical Medicine, University of Oslo, Oslo, Norway, Oslo, Norway, ³Institute for Experimental Medical Research, Oslo University Hospital and University of Oslo, Oslo, Norway, Oslo, Norway, ⁴Norwegian National Advisory Unit on Rheumatic Diseases in Children and Adolescents, Oslo University Hospital, Rikshospitalet, Oslo, Norway, Oslo, Norway
Background/Purpose: All previous studies of disease outcome in juvenile dermatomyositis (JDM) patients have been based on retrospective data or cross sectional examination. We aimed to…
Abstract Number: 1500 • 2016 ACR/ARHP Annual Meeting
Concomitant Development of Interstitial Pneumonia Associated with Dermatomyositis and Rheumatoid Arthritis
Takeshi Shoda^1,2, Tohru Takeuchi³, Kentaro Isoda⁴, Takao Kiboshi⁴ and Shigeki Makino³, ¹Division of Clinical Immunology and Rheumatology, Osaka medical college, Osaka, Japan, ²Department of Rheumatology, Yodogawa Christian Hospital, Osaka, Japan, ³Osaka medical college, Osaka, Japan, ⁴Yodogawa Christian Hospital, Osaka, Japan
Background/Purpose: A few cases of the concomitant development of interstitial pneumonia associated with dermatomyositis (DM-IP) and rheumatoid arthritis (RA) have been reported mainly in Asia,…
Abstract Number: 2103 • 2016 ACR/ARHP Annual Meeting
Peripheral Blood B Cells Are Expanded and Their Cytokine Expression Is Dysregulated in Juvenile Dermatomyositis
Meredyth Wilkinson¹, Christopher Piper², Georg Otto³, Claire Deakin⁴, Stefanie Dowle³, Stefania Simou⁵, Daniel Kelberman³, Yiannis Ioannou⁶, Claudia Mauri⁷, Elizabeth Jury⁸, David Isenberg⁹, Lucy R Wedderburn¹⁰ and Kiran Nistala¹¹, ¹Division of Medicine, University College London, London, United Kingdom, ²Rheumatology, University College London, London, United Kingdom, ³National Institute for Health Research Biomedical Research Centre at Great Ormond Street Hospital for Children NHS Foundation Trust, London, United Kingdom, ⁴Infection, Inflammation and Rheumatology Section,, UCL Institute of Child Health, London, United Kingdom, ⁵Infection, Inflammation and Rheumatology, UCL Institute of Child Health, London, United Kingdom, ⁶Arthritis Research UK Centre for Adolescent Rheumatology, University College London, London, United Kingdom, ⁷Division of Medicine, Centre for Rheumatology Research, University College London, University College London, London, United Kingdom, ⁸Division of Medicine, Centre for Rheumatology Research, University College London, London, United Kingdom, ⁹University College Hospital, London, London, United Kingdom, ¹⁰Infection, Inflammation and Rheumatology Section, UCL Institute of Child Health, London, United Kingdom, ¹¹Centre for Rheumatology, University College London, London, United Kingdom
Background/Purpose: Juvenile dermatomyositis (JDM) is a rare form of childhood autoimmune myositis that presents with proximal muscle weakness and heliotrope rash. B cells are strongly…
Abstract Number: 2236 • 2016 ACR/ARHP Annual Meeting
Effects of Repository Corticotropin Injection on Medication Use in Patients with Rheumatologic Conditions: A Claims Data Study
Gihyun Myung¹, Winnie Nelson² and Maureen A. McMahon³, ¹Division of Rheumatology/Department of Internal Medicine, University of California-Los Angeles, Los Angeles, CA, ²Health Economics and Outcomes Research, Mallinckrodt Pharmaceuticals, Hampton, NJ, ³University of California-Los Angeles, David Geffen School of Medicine, Division of Rheumatology, Los Angeles, CA
Background/Purpose: Repository corticotropin injection (RCI) may produce anti-inflammatory and immune-modulatory effects. This study examined the demographics of those who used RCI and the trends in…
Abstract Number: 2373 • 2015 ACR/ARHP Annual Meeting
Frequency of Antinuclear (ANA), Myositis-Specific (MSA) and Myositis-Associated Antibodies (MAA) in Patients with Idiopathic Inflammatory Myopathies (IIM) from Mexico, Central and South America Centers: Data from the Panlar Myositis Study Group.
Yelitza Gonzalez-Bello^1,2, Daniel Garcia-Cerda³, Gabriel Medrano-Ramírez⁴, José E. Navarro-Zarza⁵, Lilia Andrade-Ortega⁶, Marco Maradiaga-Ceceña⁷, Alicia Cardenas-Anaya⁸, Arnulfo H. Nava-Zavala^3,9, Gerardo Orozco-Barocio⁸, Armando Rojo-Mejia¹⁰, Esthela Loyo¹¹, Paola Gottschalk¹¹, Graciela Gómez¹², Marvin J. Fritzler¹³ and Ignacio Garcia-De La Torre⁸, ¹Immunology and Rheumatlogy, Universidad de Guadalajara, Zapopan, Jalisco, Mexico, ²Immunology and Rheumatology, Hospital General de Occidente, Secretaria de Salud Jalisco, Guadalajara, Jalisco, Mexico, ³Immunology and Rheumatology, Hospital General de Occidente, Secretaria de Salud Jalisco, Zapopan, Jal., Mexico, ⁴Rheumatology, Hospital General de Mexico, Secretaria de Salud, Mexico City, Mexico, ⁵Medicine, Hospital General Raymundo Abarca Alarcón, Chilpancingo, Mexico, ⁶Rheumatology, Centro Medico Nacional 20 de Noviembre, ISSSTE, Mexico City, Mexico, ⁷Rheumatology, Hospital General de Culiacan de la Secretaría de Salud, Culiacan, Sin., Mexico, ⁸Immunology and Rheumatology, Hospital General de Occidente, Secretaria de Salud Jalisco, Zapopan, Jalisco, Mexico, ⁹UMAE, Hospital de Especialidades Centro Médico Nacional de Occidente, IMSS, Guadalajara, Jalisco, Mexico, ¹⁰Rheumatology, Clinica San Pablo, Lima, Peru, ¹¹Rheumatology, Hospital Regional Universitario, Santiago, Dominican Republic, ¹²Rheumatology, Instituto de Investigaciones Medicas Alfredo Lanari, Buenos Aires, Argentina, ¹³Medicine, University of Calgary, Calgary, AB, Canada
Background/Purpose: Dermatomyositis (DM) and polymyositis (PM) are forms of IIM that involve skeletal muscle as well as many other organs. As in other systemic rheumatic…
Abstract Number: 2376 • 2015 ACR/ARHP Annual Meeting
Clinical Features in Dermatomyositis Patients with Novel Autoantibody to Small Ubiquitin-like Modifier Activating Enzymes (Anti-SAE Antibody) and Relationship to Interstitial Lung Disease: A Systematic Review of 29 Cases
Sirada Panupattanapong¹, Jessica Sun² and Kevin Baszis¹, ¹Pediatrics, Division of Rheumatology, Washington University School of Medicine, St. Louis Children's Hospital, St. Louis, MO, ²Pediatric, Division of Rheumatology, Washington University School of Medicine, St. Louis Children's Hospital, St. Louis, MO
Background/Purpose: Anti-SAE antibody is a novel myositis-specific antibody first described in 2007. SAE is an enzyme that facilitates sumoylation, leading to the formation of stable…
Abstract Number: 2380 • 2015 ACR/ARHP Annual Meeting
Jo-1 Positive Myositis Patients Tend to Have More Severe Muscle and Lung Involvement Than PM-Scl Positive Patients
Julie J. Paik¹, Arash Lahoutiharahdashti², Andrew Mammen³ and Lisa Christopher-Stine⁴, ¹Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³Center Tower Ste 5300, Johns Hopkins University School of Medicine, Baltimore, MD, ⁴Ste 4100 Rm 409, Johns Hopkins University School of Medicine, Baltimore, MD
Jo-1 positive myositis patients tend to have more severe muscle and lung involvement than PM-Scl positive patients Background/Purpose: Jo-1 and PM-Scl positive myositis patients share…
Abstract Number: 2421 • 2015 ACR/ARHP Annual Meeting
Experience with Adalimumab for Treatment of 568 Juvenile Idiopathic Arthritis Patients in the German JIA Biologics Register
Gerd Horneff¹, Gerd Ganser², Ivan Foeldvari³, Johannes Peter Haas⁴, Toni Hospach⁵, Ralf Trauzeddel⁶, Frank Weller-Heinemann⁷, J B. Kuemmerle-Deschner⁸, Angelika Thon⁹ and BIKER study group, ¹Asklepios Clinic Sankt Augustin, Sankt Augustin, Germany, ²Pediatric Rheumatology, Sankt Josef Stift, Sendenhorst, Germany, ³Rheumatology, Scleroderma, Hamburg, Germany, ⁴German Centre for Rheumatology in Children and Young People, Garmisch-Partenkirchen, Germany, ⁵Pediatrics, Olgahospital, Klinikum Stuttgart, Stuttgard, Germany, ⁶HELIOS Klinikum Berlin-Buch Klinik fuer Kinder- und Jugendmedizin, Berlin, Germany, ⁷PRINTO, Genoa, Italy, ⁸Pediatrics, University Hospital Tuebingen, Tuebingen, Germany, ⁹Kinderklinik der Medizinischen Hochschule Hannover, Hannover, Germany
Background/Purpose: Adalimumab (ADA) has become a valuable option for treatment of juvenile idiopathic arthritis (JIA), which significantly improves the outcome of patients. The aim of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].